{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/coronavirus-covid-19/management/immunization/","result":{"pageContext":{"chapter":{"id":"1e4e7529-8d5b-52a4-97cc-a86c6d93dfc8","slug":"immunization","fullItemName":"Scenario: Immunization","depth":2,"htmlHeader":"<!-- begin field 8eba7c23-094d-45d5-b3d5-ac8600a6478a --><h2>Scenario: Immunization</h2><!-- end field 8eba7c23-094d-45d5-b3d5-ac8600a6478a -->","summary":"Covers the immunization of people with COVID-19 vaccine in primary care, in line with the national COVID-19 vacination programme.","htmlStringContent":"<!-- begin item 08277640-f304-4a27-b293-5ac49f24d2dc --><!-- begin field e25b47ca-15e7-4172-851b-acd900ac53e5 --><p>From age 18 years onwards.</p><!-- end field e25b47ca-15e7-4172-851b-acd900ac53e5 --><!-- end item 08277640-f304-4a27-b293-5ac49f24d2dc -->","topic":{"id":"6984fb85-3c40-5450-bda6-7957f9a560d7","topicId":"b76b302e-7ac5-44a1-aad7-ab8700c41ab2","topicName":"Coronavirus - COVID 19","slug":"coronavirus-covid-19","lastRevised":"Last revised in February 2021","chapters":[{"id":"d212a92c-0add-595b-a7d6-5a32867fe5f9","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"1d145562-2683-52db-accf-a80bedd6bb5e","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"c52a3c97-1e7c-58b4-af86-0dd2f0b77865","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"f349cd0f-cb0c-5006-b63f-5a30fdaa06b8","slug":"changes","fullItemName":"Changes"},{"id":"f026a20a-e43c-59e7-883d-f0d7a1dbdd1a","slug":"update","fullItemName":"Update"}]},{"id":"bfc8a3e9-5b8f-5b1f-9059-3f9b1843015d","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"1d7208d4-4be1-5109-a3fc-f5fc9070f775","slug":"goals","fullItemName":"Goals"},{"id":"b64f49e4-a62d-56cd-abcb-f82c407e52e7","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"51ea8ac4-fd38-524d-8566-e42974bfa9c4","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"216d80a9-a8e3-5739-b592-c2d9ddd176ea","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"cde80e77-2bd9-5594-9200-fe3a6fef7fc3","slug":"qipp","fullItemName":"QIPP"},{"id":"a24c3e94-065a-5767-9d41-cb69868045fc","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"18477846-110b-5a6f-844c-2cfa1a84c39f","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"a15744df-f80f-5b08-8993-b289c88d56a1","slug":"definition","fullItemName":"Definition"},{"id":"814f7a41-46c7-5e8c-9763-f02d81a30777","slug":"prevalence","fullItemName":"Prevalence"},{"id":"e0a5f4e3-6adc-56a8-a13a-460ca5f3c39a","slug":"complications","fullItemName":"Complications"},{"id":"cd8348b4-2bcc-59c6-9dbf-b420df79dbfd","slug":"public-health-response","fullItemName":"Public Health Response"},{"id":"11cbcb38-8a55-5f6a-8077-321789f26356","slug":"comparison-to-other-infections","fullItemName":"Comparison to Other Infections"},{"id":"448d1049-b54d-50a4-8a5e-aac889069c6f","slug":"disease-progression","fullItemName":"Disease Progression"}]},{"id":"020a4b1b-6b82-532a-8050-185d648bcf7d","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"fc5a288c-4b1e-54d0-8244-d5ca25652c50","slug":"diagnosis","fullItemName":"Diagnosis"}]},{"id":"9ff88f37-df6c-5191-bcfc-dae33da6a3b4","fullItemName":"Management","slug":"management","subChapters":[{"id":"3c0ddcd5-473d-5a66-8ae2-7fa97ad2e887","slug":"suspected-coronavirus-infection","fullItemName":"Scenario: Suspected coronavirus infection"},{"id":"1e4e7529-8d5b-52a4-97cc-a86c6d93dfc8","slug":"immunization","fullItemName":"Scenario: Immunization"},{"id":"e148d0d4-0f10-53c6-94bf-27e92c5eb531","slug":"management-of-other-medical-conditions","fullItemName":"Scenario: Management of other medical conditions"},{"id":"18839f74-7d09-5801-9fc9-1ca496cccf09","slug":"palliative-care","fullItemName":"Scenario: Palliative care"},{"id":"ed0623a0-a868-5776-bbdb-09a5d64bd6d0","slug":"prescribing-issues","fullItemName":"Scenario: Prescribing issues"},{"id":"f6aa749f-0a06-5ca2-b3cd-e01327e4ef76","slug":"managing-long-term-effects","fullItemName":"Scenario: Managing long-term effects"},{"id":"8d7143f7-6842-52e2-8644-5060222c472f","slug":"clinical-resources","fullItemName":"Scenario: Clinical resources"}]},{"id":"ee648ec4-3617-53c8-b0d5-ade1caeb5cfb","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"3ea7d7ae-64e1-581e-856d-9daa5d3570ba","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"d29ccf56-f68d-5ce0-b726-09ba9ed827e7","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"84321e07-ed6b-5815-b7a9-de40ab2acde2","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"cfaeb9ab-79ce-5851-a900-fdd0ab56f8fd","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f73f8f10-2617-514f-b07d-8f52fb8e7f2f","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"586fa044-aa51-5fdc-895a-922bedd17946","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"66b3f0cb-7cb5-5f38-8632-30b8411234e4","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"9ff88f37-df6c-5191-bcfc-dae33da6a3b4","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"3e5c6e87-bfaa-5e2b-9e56-d81aca6ba4b6","slug":"who-to-immunize","fullItemName":"Who to immunize","depth":3,"htmlHeader":"<!-- begin field 8b28887b-cfcd-4f7a-80dc-ac8600a6478b --><h3>Who should be offered COVID-19 immunization?</h3><!-- end field 8b28887b-cfcd-4f7a-80dc-ac8600a6478b -->","summary":null,"htmlStringContent":"<!-- begin item d81a5489-20d4-4e76-8b1d-4316a1b5122f --><!-- begin field 7d2c7346-bd7f-4767-b460-ac8600a6478b --><div>Priority groups for COVID-19 vaccination advised by the Joint Committee on Vaccination and Immunisation (in order of priority) are:</div><ul><li>Residents in a care home for older adults, and staff working in care homes for older adults.</li><li>All people aged 80 years and over, and health and social care workers.<ul><li><div>All frontline healthcare staff who are eligible for the influenza vaccination should be offered the COVID-19 vaccine, including:</div><ul><li><div>Staff involved in direct patient care.</div></li><li>Non-clinical staff in secondary or primary care/community healthcare settings.</li><li>Laboratory and pathology staff.</li></ul></li></ul></li><li>All people aged 75 years and over.</li><li>All people aged 70 years and over, and clinically vulnerable individuals (not including pregnant women and people aged under 18 years).</li><li>All people aged 65 years and over.</li><li>People aged 18–65 years in at-risk groups.</li><li>All people aged 60 years and over.</li><li>All people aged 55 years and over.</li><li>All people aged 50 years and over.</li></ul><!-- end field 7d2c7346-bd7f-4767-b460-ac8600a6478b --><!-- end item d81a5489-20d4-4e76-8b1d-4316a1b5122f -->","subChapters":[{"id":"20fbdbd1-9dd1-52a5-b7e0-156b35d6e44e","slug":"clinical-risk-groups","fullItemName":"Clinical risk groups","depth":4,"htmlHeader":"<!-- begin field d26659e9-617f-4d60-afbe-ac8600d0236a --><h4>What are the clinical risk groups?</h4><!-- end field d26659e9-617f-4d60-afbe-ac8600d0236a -->","summary":null,"htmlStringContent":"<!-- begin item 12aa2dbd-d6bb-4046-820c-0e4f319c0df3 --><!-- begin field 2f312cb3-40b8-45d7-84ac-ac8600d0236a --><ul><li>Clinical risk groups, aged 18 years and over, who should receive the COVID-19 vaccination are outlined in Table 1.</li><li>Note: this list is not exhaustive, and clinicians should apply clinical judgment to take into account the risk of COVID-19 exacerbating any underlying disease, as well as the risk of serious illness from COVID-19 itself. COVID-19 vaccine should be offered in such cases even if the individual is not in the clinical risk groups specified. </li></ul><p><strong>Table 1.</strong> Clinical risk groups</p><table data-table-id=\"6c26d610-8a2e-42a6-b1bf-acce014f94ef\"><thead><tr><th scope=\"col\"><p><strong>Clinical risk group</strong></p></th><th scope=\"col\"><strong>Representative examples</strong></th></tr></thead><tbody><tr><td>Chronic respiratory disease</td><td>People with a severe lung condition, including asthma that requires continuous or repeated use of systemic steroids or with previous exacerbations requiring hospital admission; chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysema; bronchiectasis; cystic fibrosis; interstitial lung fibrosis; pneumoconiosis; and bronchopulmonary dysplasia (BPD)</td></tr><tr><td>Chronic heart disease and vascular disease </td><td><p>Congenital heart disease, hypertension with cardiac complications, chronic heart failure, individuals requiring regular medication and/or follow up for ischaemic heart disease, including people with atrial fibrillation, peripheral vascular disease, or a history of venous thromboembolism</p></td></tr><tr><td>Chronic kidney disease (CKD)</td><td>CKD stages 3, 4 or 5, chronic kidney failure, nephrotic syndrome, kidney transplantation</td></tr><tr><td>Chronic liver disease </td><td><p>Cirrhosis, biliary atresia, chronic hepatitis</p></td></tr><tr><td>Chronic neurological disease</td><td><p>Stroke, transient ischaemic attack (TIA)</p><p>Conditions in which respiratory function may be compromised due to neurological disease (e.g. polio syndrome sufferers). This includes individuals with cerebral palsy, severe or profound learning disabilities, Down’s Syndrome, multiple sclerosis, epilepsy, dementia, Parkinson’s disease, motor neurone disease and related or similar conditions; or hereditary and degenerative disease of the nervous system or muscles; or severe neurological disability</p></td></tr><tr><td>Diabetes mellitus</td><td><p>Type 1 diabetes, type 2 diabetes requiring insulin or oral hypoglycaemic drugs, diet-controlled diabetes</p></td></tr><tr><td>Immunosuppression</td><td><p>Immunosuppression due to disease or treatment, including people undergoing chemotherapy leading to immunosuppression, people undergoing radical radiotherapy, solid organ transplant recipients, bone marrow or stem cell transplant recipients, HIV infection at all stages, multiple myeloma or genetic disorders affecting the immune system (e.g. IRAK-4, NEMO, complement disorder, SCID)</p><p>People receiving immunosuppressive or immunomodulating biological therapy including, but not limited to, anti-TNF, alemtuzumab, ofatumumab, rituximab, people receiving protein kinase inhibitors or PARP inhibitors, and individuals treated with steroid-sparing agents such as cyclophosphamide and mycophenolate mofetil</p><p>People treated with or likely to be treated with systemic steroids for more than a month at a dose equivalent to prednisolone at 20 mg or more per day (any age)</p><p>Anyone with a history of haematological malignancy, including leukaemia, lymphoma, and myeloma, and those with systemic lupus erythematosus, rheumatoid arthritis, and psoriasis who may require long-term immunosuppressive treatments</p><p>Some people who are immunocompromised may have a suboptimal immunological response to the vaccine</p></td></tr><tr><td><p>Asplenia or dysfunction of the spleen</p></td><td><p>This also includes conditions that may lead to splenic dysfunction, such as homozygous sickle cell disease, thalassemia major, and coeliac syndrome</p></td></tr><tr><td>Morbid obesity</td><td>A body mass index (BMI) of 40 kg per m<sup>2</sup> or greater</td></tr><tr><td>Severe mental illness</td><td><p>People with schizophrenia or bipolar disorder, or any mental illness that causes severe functional impairment</p></td></tr><tr><td>Adult carers</td><td><p>People in receipt of a carer’s allowance, or those who are the main carer of an elderly or disabled person whose welfare may be at risk if the carer falls ill</p></td></tr><tr><td><p>Adult household members, close contacts, and carers of immunocompromised adults (individuals who expect to share living accommodation on most days, or those providing regular care, where continuing close contact is unavoidable)</p></td><td><p>Adult household contacts of immunocompromised adults who are eligible for vaccination (given the likely lower effectiveness of vaccination in this group)</p></td></tr><tr><td><p>Younger adults in long-stay nursing and residential care settings</p></td><td><p>Many younger adults in residential care settings will be eligible for vaccination because they fall into one of the clinical risk groups above. Given the likely high risk of exposure in these settings, where a high proportion of the population would be considered eligible, vaccination of the whole resident population is recommended</p><p>Younger residents in care homes for the elderly will be at high risk of exposure, and although they may be at lower risk of mortality than older residents they should not be excluded from vaccination programmes</p></td></tr><tr><td colspan=\"2\"><p><strong>Source: </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/coronavirus-covid-19/references/\">PHE, 2020d</a>]</p></td></tr></tbody></table><!-- end field 2f312cb3-40b8-45d7-84ac-ac8600d0236a --><!-- end item 12aa2dbd-d6bb-4046-820c-0e4f319c0df3 -->","subChapters":[]},{"id":"d79161ef-6b92-53cc-8042-e135cd514c5e","slug":"basis-for-recommendation-bfc","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field eeac3c65-ef0e-4c1b-bcf5-ac8600a6478b --><h4>Basis for recommendation</h4><!-- end field eeac3c65-ef0e-4c1b-bcf5-ac8600a6478b -->","summary":null,"htmlStringContent":"<!-- begin item bfcbacee-b4d0-4e67-8a72-e03cd7d0b438 --><!-- begin field 69aa2a1e-970f-4a6a-854c-ac8600a6478b --><p>These recommendations are based on chapter 14a on <em>COVID-19</em> in the Public Health England (PHE) 'Green book' [<a class=\"bibliography-reference internal-reference\" href=\"/topics/coronavirus-covid-19/references/\">PHE, 2020d</a>].</p><!-- end field 69aa2a1e-970f-4a6a-854c-ac8600a6478b --><!-- end item bfcbacee-b4d0-4e67-8a72-e03cd7d0b438 -->","subChapters":[]}]},{"id":"b0294f01-11e1-5842-bbba-367097e82e87","slug":"covid-19-vaccines-available","fullItemName":"COVID-19 vaccines available","depth":3,"htmlHeader":"<!-- begin field fa51dc08-3bc1-4104-88ea-ac8600a6478b --><h3>What vaccines are available?</h3><!-- end field fa51dc08-3bc1-4104-88ea-ac8600a6478b -->","summary":null,"htmlStringContent":"<!-- begin item dcca113e-ade6-4ddc-b8a9-584f88ea97f9 --><!-- begin field 2b8c1db4-d9c3-43cd-94b0-ac8600a6478b --><ul><li>In the UK two vaccines targeting the S protein are expected to be authorized for supply first.</li><li>The Pfizer BioNTech COVID-19 vaccine is an mRNA vaccine – there is no live virus.<ul><li>It contains the genetic sequence (mRNA) for the spike protein that is found on the surface of the SARS-CoV-2 virus, wrapped in a lipid envelope (referred to as a nanoparticle) to enable it to be transported into the cells in the body.</li><li>When injected, the mRNA is taken up by the host’s cells that translate the genetic information and produce the spike proteins. These are then displayed on the surface of the cell. This stimulates the immune system to produce antibodies and activate T-cells that prepare the immune system to respond to any future exposure to the SARS-CoV-2 virus by binding to and disabling any virus encountered.</li></ul></li><li>The AstraZeneca COVID-19 vaccine is an adenovirus vector vaccine — it uses a weakened adenovirus as a carrier to deliver the SARS-CoV-2 antigen.<ul><li>The adenovirus has been modified so that it cannot replicate in human cells and therefore cause any disease.</li><li>The genes that encode for the spike protein on the SARS-CoV-2 virus have been inserted into the adenovirus's genetic code to make the vaccine. When the vaccine is injected, it enters the host's cells that then manufacture the spike protein. This then stimulates the immune system that reacts by producing antibodies and memory cells to the SARS-CoV-2 virus without causing disease.</li></ul></li><li>See Table 1 for a comparison of the features of these vaccines. </li></ul><p><strong>Table 1.</strong> Comparison of COVID-19 vaccines</p><table data-table-id=\"b4c467b8-cdf0-4bef-8fda-acce014f9448\"><thead><tr><th scope=\"col\"><strong>Feature</strong></th><th scope=\"col\"><strong>Pfizer BioNtech</strong></th><th scope=\"col\"><strong>AstraZeneca</strong></th></tr></thead><tbody><tr><td>Effectiveness</td><td>95%</td><td>Up to 90%</td></tr><tr><td>Storage</td><td><p>-70°C +/-10°C (shelf life of 6 months)</p><p>Once thawed can be stored at 2–8°C for up to 5 days and up to 2 hours at 25°C</p><p>After dilution, at 2°C to 25°C and use within 6 hours</p></td><td><p>2–8°C (shelf life of 6 months)</p><p>After first opening, the vial should be used within 6 hours when stored at room temperature (up to 30°C), or within 48 hours if stored in a fridge</p></td></tr><tr><td>Dosing</td><td>2 doses 21 days apart</td><td><p>2 doses 28 days apart</p></td></tr><tr><td>Packaging</td><td><p>Each pack contains 195 vials, each vial contains 5 doses</p></td><td>Each pack contains 10 vials, each vial contains 8 or 10 doses</td></tr><tr><td>Dilution required</td><td><p>Yes</p></td><td>No</td></tr><tr><td colspan=\"3\"><strong>Source:</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/coronavirus-covid-19/references/\">PHE, 2020d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/coronavirus-covid-19/references/\">SPC 2020</a>]</td></tr></tbody></table><!-- end field 2b8c1db4-d9c3-43cd-94b0-ac8600a6478b --><!-- end item dcca113e-ade6-4ddc-b8a9-584f88ea97f9 -->","subChapters":[{"id":"dfdafed8-1bd3-5fd5-aa87-4d557773eb5b","slug":"basis-for-recommendation-60a","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field f9d2a2ba-7bb0-4457-a108-ac8600a6478b --><h4>Basis for recommendation</h4><!-- end field f9d2a2ba-7bb0-4457-a108-ac8600a6478b -->","summary":null,"htmlStringContent":"<!-- begin item 60a99881-7143-4b27-afdb-bf209c093e50 --><!-- begin field 80afb3ed-7457-4c94-aeae-ac8600a6478b --><p>This information is based on chapter 14a on <em>COVID-19</em> in the Public Health England (PHE) 'Green book' [<a class=\"bibliography-reference internal-reference\" href=\"/topics/coronavirus-covid-19/references/\">PHE, 2020d</a>].</p><!-- end field 80afb3ed-7457-4c94-aeae-ac8600a6478b --><!-- end item 60a99881-7143-4b27-afdb-bf209c093e50 -->","subChapters":[]}]},{"id":"78e6a2dd-6b12-57b2-9bae-bbbae3472e6d","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field e595ba25-1be4-4923-9e76-ac8600a6478b --><h3>What are the contraindications to the COVID-19 vaccine?</h3><!-- end field e595ba25-1be4-4923-9e76-ac8600a6478b -->","summary":null,"htmlStringContent":"<!-- begin item 5b709dcd-20bc-4fbe-94be-1ca42ebba944 --><!-- begin field 4148bf97-f110-4ccd-93cb-ac8600a6478b --><ul><li>There are few people who cannot receive the Pfizer BioNtech or AstraZeneca vaccines.<ul><li>If in doubt, seek advice from the relevant specialist or the local immunization or public health protection team. </li></ul></li><li>Do not give the vaccine to people who have had a confirmed anaphylactic reaction to:<ul><li>A previous dose of COVID-19 vaccine.</li><li>Any component of the vaccine.</li></ul></li><li>Postpone immunization in people who are acutely unwell — this is to avoid confusing the differential diagnosis of any acute illness (including COVID-19) by wrongly attributing any signs or symptoms to the adverse effects of the vaccine.<ul><li>Minor illness without fever or systemic upset are not reasons to postpone immunization.</li></ul></li><li>Vaccination of people who may be infected or asymptomatic or incubating COVID-19 infection is unlikely to have a detrimental effect on the illness.</li><li>Vaccination should be deferred in people with confirmed infection to avoid confusing the differential diagnosis.<ul><li>As clinical deterioration can occur up to 2 weeks after infection, ideally vaccination should be deferred until clinical recovery and at least until 4 weeks after onset of symptoms or 4 weeks from the first PCR positive specimen in those who are asymptomatic.</li></ul></li><li>Prolonged COVID-19 symptoms is not a contraindication to COVID-19 vaccine.<ul><li>However, if there is evidence of current deterioration, deferral of vaccination may be considered to avoid incorrectly attributing any change in the person’s underlying condition to the vaccine.</li></ul></li></ul><!-- end field 4148bf97-f110-4ccd-93cb-ac8600a6478b --><!-- end item 5b709dcd-20bc-4fbe-94be-1ca42ebba944 -->","subChapters":[{"id":"2b4c6eb3-340b-5c3c-a3ee-e522a13bfc3a","slug":"basis-for-recommendation-ad3","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field d4e2b61e-22c6-47f5-b11f-ac8600a6478b --><h4>Basis for recommendation</h4><!-- end field d4e2b61e-22c6-47f5-b11f-ac8600a6478b -->","summary":null,"htmlStringContent":"<!-- begin item ad38749a-b2a4-4a8e-98b4-e7cc1dbfd451 --><!-- begin field 7a0e8d2e-9dcc-47ea-8ef1-ac8600a6478b --><p>These recommendations are based on chapter 14a on <em>COVID-19</em> in the Public Health England (PHE) 'Green book' [<a class=\"bibliography-reference internal-reference\" href=\"/topics/coronavirus-covid-19/references/\">PHE, 2020d</a>], and the manufacturer's Summary of Product Characteristics for COVID-19 mRNA Vaccine BNT162b2 concentrate for solution for injection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/coronavirus-covid-19/references/\">SPC 2020</a>]. </p><!-- end field 7a0e8d2e-9dcc-47ea-8ef1-ac8600a6478b --><!-- end item ad38749a-b2a4-4a8e-98b4-e7cc1dbfd451 -->","subChapters":[]}]},{"id":"bb8d39f6-5dcf-5064-8782-5f2cdae3cf6f","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field 344a562f-1feb-4bb2-bfef-ac86010d850b --><h3>Can the COVID-19 vaccine be administered to women who are pregnant or breastfeeding?</h3><!-- end field 344a562f-1feb-4bb2-bfef-ac86010d850b -->","summary":null,"htmlStringContent":"<!-- begin item 3477d2bf-5b6a-477f-bce8-9feb86402038 --><!-- begin field 447648c4-d5b4-48e2-a728-ac86010d850b --><h4>Pregnancy</h4><ul><li>There is no known risk associated with giving inactivated, recombinant viral or bacterial vaccines or toxoids during pregnancy.</li><li>The data do not indicate any safety concerns or harm during pregnancy, but there is insufficient evidence to recommend routine use during pregnancy.</li><li>Postpone vaccination until completion of pregnancy.<ul><li>For pregnant women at high risk (including healthcare workers), offer vaccination as soon as possible after completion of pregnancy. </li></ul></li><li>Consider discussing vaccination in the small number of women who cannot avoid exposure, and who have underlying conditions that put them at very high risk of serious complications of COVID-19. <ul><li>These conditions include Down’s syndrome, cerebral palsy, homozygous sickle cell disease, motor neurone disease, chemotherapy, and chronic kidney disease. Advise these women about the absence of safety data for these vaccines.</li></ul></li><li>The manufacturer of the Pfizer BioNtech vaccine advises that pregnancy should be excluded in women of childbearing age before vaccination and that women should be advised to avoid pregnancy for at least 2 months after their second dose. </li></ul><h4>Breastfeeding</h4><ul><li>There is no known risk associated with giving inactivated, recombinant viral or bacterial vaccines or toxoids whilst breastfeeding.</li><li>It is unknown whether the Pfizer BioNtech vaccine is excreted in breastmilk and so a risk to newborns cannot be excluded. </li></ul><!-- end field 447648c4-d5b4-48e2-a728-ac86010d850b --><!-- end item 3477d2bf-5b6a-477f-bce8-9feb86402038 -->","subChapters":[{"id":"33d27635-b8d5-5ac9-b22c-1627bd16eac6","slug":"basis-for-recommendation-c32","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 49d19cc0-07cf-4d01-94ff-ac86010d850b --><h4>Basis for recommendation</h4><!-- end field 49d19cc0-07cf-4d01-94ff-ac86010d850b -->","summary":null,"htmlStringContent":"<!-- begin item c325ef95-fd1f-45c8-b20c-466212cddfae --><!-- begin field ce30675f-6536-41bf-90e4-ac86010d850b --><p>These recommendations are based on chapter 14a on <em>COVID-19</em> in the Public Health England (PHE) 'Green book' [<a class=\"bibliography-reference internal-reference\" href=\"/topics/coronavirus-covid-19/references/\">PHE, 2020d</a>], and the manufacturer's Summary of Product Characteristics for COVID-19 mRNA Vaccine BNT162b2 concentrate for solution for injection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/coronavirus-covid-19/references/\">SPC 2020</a>]. </p><!-- end field ce30675f-6536-41bf-90e4-ac86010d850b --><!-- end item c325ef95-fd1f-45c8-b20c-466212cddfae -->","subChapters":[]}]},{"id":"32519b8e-7fe7-5e89-b37f-e2edaa825658","slug":"administering-covid-19-vaccines","fullItemName":"Administering COVID-19 vaccines","depth":3,"htmlHeader":"<!-- begin field cf897343-384b-4030-b6b2-ac8600a6478b --><h3>How are the vaccines administered?</h3><!-- end field cf897343-384b-4030-b6b2-ac8600a6478b -->","summary":null,"htmlStringContent":"<!-- begin item 7375632c-9d00-4d23-a5a8-a3889daa4584 --><!-- begin field ee74301f-4d81-449d-a362-ac8600a6478b --><ul><li>All people attending for vaccination and those delivering it should wear appropriate personal protective equipment (PPE). </li><li>COVID-19 vaccines are administered by intramuscular (IM) injection into the deltoid muscle of the upper arm.<ul><li>In people with minimal muscle mass in the deltoid area, or a reason to avoid immunization into the deltoid, the vaccine can be administered in the vastus lateralis muscle in the thigh if necessary. </li><li>People with bleeding disorders can still be vaccinated intramuscularly —  if the person receives medication or treatment to reduce bleeding (for example treatment for haemophilia), IM vaccination can be scheduled shortly after such medication or treatment is administered. Use a fine needle (23 or 25 gauge) for the vaccination, followed by firm pressure applied to the site (without rubbing) for at least 2 minutes.</li></ul></li><li>Monitor vaccine recipients for 15 minutes after vaccination, with a longer observation period when indicated after clinical assessment. <ul><li>An MHRA protocol for the management of anaphylaxis and an anaphylaxis pack must always be available whenever the Pfizer/BioNTech vaccine is given. </li><li>Immediate treatment should include early treatment with 0.5 mg intramuscular adrenaline (0.5 ml of 1:1000 or 1 mg/ml adrenaline), with an early call for help and further IM adrenaline every 5 minutes.</li><li>The health professional overseeing the immunization service must be trained to recognise an anaphylactic reaction and be familiar with techniques for resuscitation of a person with anaphylaxis.</li></ul></li><li>Initially scheduling of the second dose from 28 days was recommended for both vaccines to simplify the message to the public, however, PHE now advises that the second dose can be given up to 12 weeks after the first dose.<ul><li>This change to dose schedule was prompted by the emergence of the new more highly transmissible variant of the virus, to ensure that more people benefitted from the first dose. </li></ul></li><li>If the course is interrupted or delayed, resume the course using the same vaccine, but do not repeat the first dose. <ul><li>Every effort should be made to determine which vaccine the individual received and to complete with the same vaccine as there is no evidence on interchangeability.</li><li>For individuals who started the schedule and who attend for vaccination at a site where the same vaccine is not available, or if the first product received is unknown, it is reasonable to offer a single dose of the locally available product.</li></ul></li><li>Do not routinely offer co-administration of other vaccines with COVID-19 vaccine at the same appointment — there is no data for co-administration, but interference between inactivated vaccines with different antigenic content is likely to be limited.<ul><li>Ideally, schedule other required vaccines at an interval of at least 7 days to avoid incorrect attribution of potential adverse events.</li></ul></li><li>The method of administration of the Pfizer/BioNtech vaccine is as follows:<ul><li>Transfer frozen vials to 2°C to 8°C to thaw — a 195 vial pack may take 3 hours to thaw. Alternatively, thaw for 30 minutes at temperatures up to 25°C for immediate use. <ul><li>Once thawed, the undiluted vaccine can be stored for up to 5 days at 2°C to 8°C, and up to 2 hours at temperatures up to 25°C. </li></ul></li><li>Allow the thawed vial to come to room temperature and gently invert 10 times prior to dilution. Do not shake.<ul><li>Prior to dilution, the vaccine should present as an off-white solution with no particulates visible. Discard the vaccine if particulates or discolouration are present. </li></ul></li><li>Dilute the thawed vaccine in its original vial with 1.8 mL sodium chloride 9 mg/mL (0.9%) solution for injection, using a 21 gauge or narrower needle and aseptic techniques. <ul><li>Warning: unpreserved sodium chloride 9 mg/mL (0.9%) solution for injection is the only diluent that should be used. This diluent is not provided in the vaccine carton. </li></ul></li><li>Equalize vial pressure before removing the needle from the vial by withdrawing 1.8 mL air into the empty diluent syringe. </li><li>Gently invert the diluted solution 10 times. Do not shake. </li><li>The diluted vaccine should present as an offwhite solution with no particulates visible — discard the diluted vaccine if particulates or discolouration are present. </li><li>Mark the diluted vials with the new discard date and time and store between 2°C to 25°C. Use immediately, and within 6 hours after dilution.</li><li>After dilution, the vial contains 5 doses of 0.3 mL. Withdraw the required 0.3 mL dose of diluted vaccine using a sterile needle and syringe and discard any unused vaccine within 6 hours after dilution.</li></ul></li><li><strong>Note:</strong> this information was correct on 11 December 2020. The latest Primary Care Guidance on the COVID-19 vaccination programme is available on the <a href=\"https://www.england.nhs.uk/coronavirus/covid-19-vaccination-programme/primary-care-guidance/\" data-hyperlink-id=\"34751444-62c2-432d-9689-ac8e0091d938\">NHS England</a> website, including the <a href=\"https://www.england.nhs.uk/coronavirus/publication/standard-operating-procedure-covid-19-local-vaccination-services-deployment-in-community-settings/\" data-hyperlink-id=\"d8a246c2-e6af-4015-af47-ac8e0091d938\">Standard operating procedure: COVID-19 local vaccination services deployment in community setting</a>.</li></ul><!-- end field ee74301f-4d81-449d-a362-ac8600a6478b --><!-- end item 7375632c-9d00-4d23-a5a8-a3889daa4584 -->","subChapters":[{"id":"fb02499b-dbfe-508e-bf46-fbdfb427ed45","slug":"basis-for-recommendation-bcf","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 92575af6-7c00-490c-a3e2-ac8600a6478b --><h4>Basis for recommendation</h4><!-- end field 92575af6-7c00-490c-a3e2-ac8600a6478b -->","summary":null,"htmlStringContent":"<!-- begin item bcf03a44-6b04-48c0-945c-cac54d6d969e --><!-- begin field 63e7c2cb-47c9-4310-9267-ac8600a6478b --><p>These recommendations are based on chapter 14a on<em> COVID-19</em> in the Public Health England (PHE) 'Green book' [<a class=\"bibliography-reference internal-reference\" href=\"/topics/coronavirus-covid-19/references/\">PHE, 2020d</a>], the manufacturer's Summary of Product Characteristics for COVID-19 mRNA Vaccine BNT162b2 concentrate for solution for injection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/coronavirus-covid-19/references/\">SPC 2020</a>], the PHE document <em>COVID-19 vaccination programme. Information for healthcare practitioners</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/coronavirus-covid-19/references/\">PHE, 2020e</a>], and the NHS England (NHSE) <em>Standard operating procedure: COVID-19 local vaccination services deployment in community settings </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/coronavirus-covid-19/references/\">NHSE, 2020</a>].</p><!-- end field 63e7c2cb-47c9-4310-9267-ac8600a6478b --><!-- end item bcf03a44-6b04-48c0-945c-cac54d6d969e -->","subChapters":[]}]},{"id":"3f091b7a-2d7e-5405-9d19-895f6bc3493f","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 201e4715-e04e-4463-acc1-ac8600a6478b --><h3>What are the adverse effects?</h3><!-- end field 201e4715-e04e-4463-acc1-ac8600a6478b -->","summary":null,"htmlStringContent":"<!-- begin item 014ffa04-6b22-4bda-8c68-7468647df1a0 --><!-- begin field a73d92a6-7278-48b9-9594-ac8600a6478b --><ul><li>Common or very common adverse effects include:<ul><li>Local injection site reactions, such as pain, swelling, redness, tenderness.</li><li>Fatigue.</li><li>Headache.</li><li>Chills.</li><li>Myalgia.</li><li>Arthralgia.</li><li>Pyrexia.</li><li>Nausea.</li></ul></li><li>Rare adverse effects include:<ul><li>Anaphylaxis.</li></ul></li><li>COVID-19 vaccines are black triangle drugs, any adverse reactions should be reported to the MHRA using the <a href=\"https://yellowcard.mhra.gov.uk/\" data-hyperlink-id=\"cac1efcb-fd46-4cd3-8899-ac8700a66a50\">Yellow Card Scheme</a>.</li></ul><!-- end field a73d92a6-7278-48b9-9594-ac8600a6478b --><!-- end item 014ffa04-6b22-4bda-8c68-7468647df1a0 -->","subChapters":[{"id":"dec03cf1-fe62-5b1e-9d82-97302577b33c","slug":"basis-for-recommendation-d1c","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 014fa6fe-0bb9-4750-8ed4-ac8600a6478b --><h4>Basis for recommendation</h4><!-- end field 014fa6fe-0bb9-4750-8ed4-ac8600a6478b -->","summary":null,"htmlStringContent":"<!-- begin item d1c1229d-4123-499f-9912-3292c99e7452 --><!-- begin field 864dfa6d-010b-4465-a5fb-ac8600a6478b --><p>This information is based on chapter 14a on <em>COVID-19</em> in the Public Health England (PHE) 'Green book' [<a class=\"bibliography-reference internal-reference\" href=\"/topics/coronavirus-covid-19/references/\">PHE, 2020d</a>], and the manufacturer's Summary of Product Characteristics for COVID-19 mRNA Vaccine BNT162b2 concentrate for solution for injection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/coronavirus-covid-19/references/\">SPC 2020</a>]. </p><!-- end field 864dfa6d-010b-4465-a5fb-ac8600a6478b --><!-- end item d1c1229d-4123-499f-9912-3292c99e7452 -->","subChapters":[]}]},{"id":"606b0cce-6c26-5475-a9af-e8f6993ca696","slug":"information-advice","fullItemName":"Information and advice","depth":3,"htmlHeader":"<!-- begin field 8e0fa2a1-3ae2-4d39-a8f8-ac8600a6478b --><h3>What information and advice should I give people receiving the COVID-19 vaccine?</h3><!-- end field 8e0fa2a1-3ae2-4d39-a8f8-ac8600a6478b -->","summary":null,"htmlStringContent":"<!-- begin item ede971a7-cae1-4858-868f-7115cb779a72 --><!-- begin field 760c5540-f431-4ad7-bf75-ac8600a6478b --><ul><li>Advise people: <ul><li>That the vaccine may cause a mild fever that usually resolves within 48 hours — this is a common, expected reaction and isolation is not required unless COVID-19 is suspected.</li><li>About other possible adverse effects and how to report them.</li><li>Not to drive for 15 minutes after vaccination.</li><li>When they need to return for the second dose and the arrangements.</li></ul></li></ul><!-- end field 760c5540-f431-4ad7-bf75-ac8600a6478b --><!-- end item ede971a7-cae1-4858-868f-7115cb779a72 -->","subChapters":[{"id":"b1838aab-2e2d-5be9-8e9c-9cd5772430a7","slug":"basis-for-recommendation-402","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field a3706564-e27c-47bf-b95a-ac8600a6478b --><h4>Basis for recommendation</h4><!-- end field a3706564-e27c-47bf-b95a-ac8600a6478b -->","summary":null,"htmlStringContent":"<!-- begin item 4028e5d9-a4be-4bc5-87ed-1f0536ce7a19 --><!-- begin field d182cfd4-7430-475f-a917-ac8600a6478b --><p>These recommendations are based on chapter 14a on<em> COVID-19</em> in the Public Health England (PHE) 'Green book' [<a class=\"bibliography-reference internal-reference\" href=\"/topics/coronavirus-covid-19/references/\">PHE, 2020d</a>], the PHE document <em>COVID-19 vaccination programme. Information for healthcare practitioners</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/coronavirus-covid-19/references/\">PHE, 2020e</a>], and what CKS considers good medical practice. </p><!-- end field d182cfd4-7430-475f-a917-ac8600a6478b --><!-- end item 4028e5d9-a4be-4bc5-87ed-1f0536ce7a19 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}